Table 1 Collected data throughout the REFRACT-LYMA cohort study

 Age

X

 Sex

X

 Education

X

 Profession^a

X

 Living situation^a

X

 Place of residence^a

X

 Ethnicity

X

 Number of children^a

X

 Death information^a

 Body weight and height^a

X

 Physical activities^a

X

 Smoking and alcohol habits^a

X

 Family history of cancer

X

 Personal history of lymphoma

X

 Constitutive or acquired immunodeficiency

X

 ECOG performance status

X

X

X

X

X

X

X

X

 Disease status

X

X

X

X

X

X

X

X

 Ann Arbor staging

X

X

X

X

X

 IPI

X

X

X

X

X

 MIPI

X

X

X

X

X

 Splenomegaly

X

X

X

X

X

 Digestive expression of lymphoma

X

X

X

X

X

 Circulating tumor cells

X

X

X

X

X

 Number of extranodal territories

X

X

X

X

X

 Serum lactate dehydrogenase level

X

X

X

X

X

 Creatinine level

X

X

X

X

X

 Hemoglobin concentration

X

X

X

X

X

 White blood cell count

X

X

X

X

X

 Bone marrow biopsy data

X

X

X

X

X

 Tumor cell cytological morphology

X

X

X

X

X

 Molecular markers

X

X

X

X

X

 Genetic abnormality: t(11,14) and del17

X

X

X

X

X

 B-cell and MCL markers

X

X

X

X

X

 Monoclonality

X

X

X

X

X

 MRD

X

X

X

X

X

X

 PET data

X

X

X

X

X

 Adverse events

X

X

X

X

X

X

X

X

 Treatment characteristics

X

X

X

X

X

X

 CIRS-G^a

X

 Quality of life

X

X

X

X

X

X

X

X

 Biological samples: blood sample, bone marrow, lymph node, pleural effusion, cerebrospinal fluid

X

X

X

X

X

X

 Flow cytometry

X

X

X

X

X

X

 RNA analysis:

X

X

X

X

X

X

 Functional assays

X

X

X

X

X

X